News

Article

Cancer Research Technology and SV Life Sciences Launch Company

CRT and SV Life Sciences launched Artios Pharma, a new company formed to develop drugs targeting the DNA damage response to cancer.

On Sept. 21, 2016 Cancer Research Technology (CRT), the development and commercialization arm of Cancer Research UK, and SV Life Sciences announced the launch of Artios Pharma, a new company formed to develop drugs targeting the DNA damage response in cancer. Artios has licensed two lead DNA damage response programs from CRT and has signed a research collaboration agreement with CRT Discovery Laboratories. Artios will work with CRT Discovery Laboratories to progress these programs and discover and develop drug targets from Cancer Research UK’s portfolio of DNA damage repair research.

“Targeting the DNA damage response is an exciting and promising field of biology with growing interest following the recent success of PARP inhibitors. DNA damage response drug products have the potential to become established as first-line treatments, either as single agents or for use in combination with many approved therapies,” Niall Martin, CEO of Artios Pharma, said in a statement. “It is an ideal time for Artios to be entering the field as a DNA damage response-focused, independent biotech company. We’re delighted to welcome our world-class investors to the company and to announce our first partnership with Cancer Research Technology.”

Under the terms of the agreements, CRT will receive research funding into its Discovery Laboratories, equity in the company, and be eligible to receive milestone payments and royalties on projects advancing through Artios’ drug pipeline. The company’s lead program targets the pol-theta molecule and builds on cell biology research from Professor Gillies McKenna’s and Dr. Geoff Higgins’ laboratories at the Cancer Research UK/MRC Oxford Institute for Radiation Biology. The pol-theta molecule is thought to control DNA repair processes in certain tumors. Knocking out the target could remove a vital path relied on by the cancer cell, causing it to die. A second program against an undisclosed target has also been licensed to Artios.

Source: CRT 

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content